Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

s in addition to our prior cash reserves provides us with approximately four years of cash, which we believe is sufficient to complete all three OGX-011/TV1011 (custirsen) Phase 3 trials including the Phase 3 trial in non-small cell lung cancer (NSCLC) that we expect to initiate next year."

"In addition, we now have the financial capacity to expand the OGX-427 program into a second randomized Phase 2 clinical trial. This proposed trial will evaluate OGX-427 in combination with standard chemotherapy as first-line treatment for metastatic bladder cancer, and will enroll approximately 180 patients," added Cormack. "Due to begin in 2011, this trial will complement the ongoing randomized Phase 2 clinical trial in prostate cancer, and Phase 1 clinical trial in superficial bladder cancer. Like custirsen, OGX-427 has broad potential for therapeutic benefit across a number of tumor types including bladder cancer, the fifth most common form of cancer. This underserved patient population is in desperate need of new treatment options." The Company reported a loss for the quarter ended September 30, 2010 of $6.9 million. As of September 30, 2010, cash and investment securities totalled $42.1 million. Together with the estimated $46.7 million proceeds from our October financing, and based on current and planned development activities, management believes existing cash and investment securities will provide adequate resources to fund the Company's currently planned operations into late 2014. Additional Recent Business Highlights

  • On November 2, 2010, the Company was notified that it had been awarded two grants totaling $489,000 under the Internal Revenue Service's Therapeutic Discovery Tax Credit Program. This program was created under the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants representing up to 50 percent of eligible qualified investments in therapeutic discovery projects during tax years 2009 and 2010. OncoGen
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
    2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
    3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
    4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
    5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
    6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
    7. OncoGenex Reports Second Quarter Financial Results
    8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
    9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
    10. OncoGenex Reports First Quarter Financial Results
    11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... have made great strides in saving China,s endangered national ... over 65 giant panda reserves that have been established ... just 1596 pandas remain in the wild. , ... save the panda by improving genetic diversity, avoid inbreeding ... how are these high-profile programs doing so far? , ...
    (Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
    (Date:7/23/2014)... SAN ANTONIO , 23 de julio de ... ADBI (ADBI o la Compañía) ha anunciado hoy ... Akron (ABIA o el Instituto), ... de ADBI, un dispositivo de terapia de señal ...   El Instituto, que tiene una ...
    (Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 /PRNewswire/ - ... industrial biotechnology company producing sustainable chemicals, today announced that ... in full their option to purchase an additional ... offering price of $12.00 per share, less underwriting ... announced underwritten public offering of 2,800,000 shares of ...
    Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
    ... senior executives from companies and government organizations will gather ... produced by ... In the foreseeable future a,trip to the doctor,s office ... Armed with our complete genetic profile information about,predisposition to disease, ...
    ... Southern Research,Institute today announced that it has ... to Virium Pharmaceuticals, Inc. To date, six of,Southern ... are on,the market. Six others, including 4,-Thio-Ara-C, are ... trials. (Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 ) ...
    ... BASINGSTOKE, England, September 13 In order,to meet its ... Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ... ended 30 June 2007,in accordance with International Financial Reporting ... 26 July 2007, Shire announced its results in,respect of ...
    Cached Biology Technology:The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco 2Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals 2IFRS Information - First Half of 2007 2IFRS Information - First Half of 2007 3IFRS Information - First Half of 2007 4IFRS Information - First Half of 2007 5IFRS Information - First Half of 2007 6IFRS Information - First Half of 2007 7IFRS Information - First Half of 2007 8IFRS Information - First Half of 2007 9IFRS Information - First Half of 2007 10IFRS Information - First Half of 2007 11IFRS Information - First Half of 2007 12IFRS Information - First Half of 2007 13IFRS Information - First Half of 2007 14IFRS Information - First Half of 2007 15IFRS Information - First Half of 2007 16IFRS Information - First Half of 2007 17IFRS Information - First Half of 2007 18IFRS Information - First Half of 2007 19IFRS Information - First Half of 2007 20IFRS Information - First Half of 2007 21IFRS Information - First Half of 2007 22IFRS Information - First Half of 2007 23IFRS Information - First Half of 2007 24IFRS Information - First Half of 2007 25IFRS Information - First Half of 2007 26IFRS Information - First Half of 2007 27IFRS Information - First Half of 2007 28IFRS Information - First Half of 2007 29IFRS Information - First Half of 2007 30IFRS Information - First Half of 2007 31IFRS Information - First Half of 2007 32IFRS Information - First Half of 2007 33
    (Date:7/23/2014)... of Antarctic fur seals, alongside decades of in-depth ... of climate change on a population of top-predators. ... findings show that the seals have significantly altered ... are associated with climate conditions. Despite a shift ... is not passing down through generations, leaving the ...
    (Date:7/23/2014)... Spinach gave Popeye super strength, but it also ... group of scientists: the ability to convert sunlight into ... are part of an international group using spinach to ... which plants convert the sun,s energy into carbohydrates used ... are part of the most efficient system ever built, ...
    (Date:7/23/2014)... July 23, 2014 Migratory songbirds are disappearing, and ... climate change, loss of habitat, acid rain and light ... missing: where do these birds go once they leave ... encountering along the way? , To answer this question, ... created the first ever migratory connectivity map produced for ...
    Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3Spinach could lead to alternative energy more powerful than Popeye 2York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2
    ... Molecular Targets and Cancer Therapeutics is the location to ... year,s conference brings together delegates from all over the ... and the impact of new discoveries in molecular and ... coverage of the conference, the program schedule is available ...
    ... is better than blending in, at least if you,re ... nest-mates determine social status. That,s the conclusion of ... this week in the journal Evolution . ... advertising your identity," said graduate student Michael Sheehan, who ...
    ... Germany, October 15, 2009 / b3c newswire / ... announced today that they will enter into collaboration. ... for the identification of novel biomarkers in a ... phosphoproteomics platform allows annotation and quantification of regulated ...
    Cached Biology News:Being a standout has its benefits, study shows 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 4
    ... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
    ... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
    ... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
    ... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
    Biology Products: